Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tabalumab in Rheumatoid Arthritis (FLEX O)
NCT01202760Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2011
- Primary completion
- Dec 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial of tabalumab in rheumatoid arthritis (RA) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: American College of Rheumatology 20% Response at 24 weeks. Started Jan 2011; status: completed.
02
Drugs
tabalumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01202760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01202760.